Stock GLUE MONTE ROSA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
5.33 USD -2.20% Intraday chart for Monte Rosa Therapeutics, Inc. -8.89% -5.66%
Mar. 14 Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline MT
Mar. 14 Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Business Summary

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Number of employees: 133

Managers

Managers TitleAgeSince
Markus Warmuth CEO
 Chief Executive Officer 53 19-12-31
Jennifer Champoux COO
 Chief Operating Officer - 21-02-28
Filip Janku CTO
 Chief Tech/Sci/R&D Officer 50 21-05-31
Sharon Townson CTO
 Chief Tech/Sci/R&D Officer 49 20-06-30
Owen Wallace CTO
 Chief Tech/Sci/R&D Officer 55 21-01-31
John Castle CTO
 Chief Tech/Sci/R&D Officer 54 20-04-30
Philip Nickson LAW
 General Counsel 45 21-02-28

Members of the board

Members of the board TitleAgeSince
Andrew Schiff BRD
 Director/Board Member 58 20-08-31
Christine Siu BRD
 Director/Board Member 47 20-11-30
Chandra Paul Leo BRD
 Director/Board Member 55 20-08-31
Ali Behbahani BRD
 Director/Board Member 47 20-03-31
Anthony Manning BRD
 Director/Board Member 62 23-07-24
Markus Warmuth CEO
 Chief Executive Officer 53 19-12-31
Jan Skvarka BRD
 Director/Board Member 57 23-03-22
Kimberly Blackwell BRD
 Director/Board Member 55 20-05-31
Alexander Mayweg CHM
 Chairman 49 18-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 50,168,769 49,720,774 ( 99.11 %) 14,696 ( 0.0293 %) 99.11 %

Shareholders

NameEquities%Valuation
Versant Venture Management LLC
17.74 %
8,897,053 17.74 % 63 M $
NEA Management Co. LLC
15.34 %
7,692,298 15.34 % 54 M $
Fidelity Management & Research Co. LLC
11.04 %
5,537,239 11.04 % 39 M $
T. Rowe Price Associates, Inc. (Investment Management)
10.16 %
5,096,787 10.16 % 36 M $
T. Rowe Price International Ltd.
9.851 %
4,940,907 9.851 % 35 M $
Baker Bros. Advisors LP
9.802 %
4,916,095 9.802 % 35 M $
Avoro Capital Advisor LLC
9.042 %
4,535,000 9.042 % 32 M $
BlackRock Advisors LLC
4.549 %
2,281,490 4.549 % 16 M $
Vanguard Fiduciary Trust Co.
3.167 %
1,588,417 3.167 % 11 M $
Aisling Capital Management LP
2.936 %
1,472,331 2.936 % 10 M $

Company contact information

Monte Rosa Therapeutics, Inc.

321 Harrison Avenue Suite 900

02118, Boston

+

http://www.monterosatx.com
address Monte Rosa Therapeutics, Inc.(GLUE)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.33 USD
Average target price
15.71 USD
Spread / Average Target
+194.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MONTE ROSA THERAPEUTICS, INC. Stock Monte Rosa Therapeutics, Inc.
-5.66% 268M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GLUE Stock
  4. Company Monte Rosa Therapeutics, Inc.